SBI Securities Co. Ltd. Invests $353,000 in Haleon plc (NYSE:HLN)

SBI Securities Co. Ltd. purchased a new stake in Haleon plc (NYSE:HLN - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 37,015 shares of the company's stock, valued at approximately $353,000.

Several other hedge funds also recently added to or reduced their stakes in HLN. Addison Advisors LLC boosted its position in shares of Haleon by 28.7% in the fourth quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after buying an additional 1,106 shares during the period. Synovus Financial Corp boosted its holdings in Haleon by 0.8% in the 3rd quarter. Synovus Financial Corp now owns 148,834 shares of the company's stock worth $1,575,000 after acquiring an additional 1,216 shares during the period. Greenleaf Trust grew its position in Haleon by 8.4% in the fourth quarter. Greenleaf Trust now owns 17,225 shares of the company's stock valued at $164,000 after acquiring an additional 1,333 shares in the last quarter. Baron Wealth Management LLC raised its stake in shares of Haleon by 4.3% during the fourth quarter. Baron Wealth Management LLC now owns 33,632 shares of the company's stock valued at $321,000 after purchasing an additional 1,381 shares during the period. Finally, Peapack Gladstone Financial Corp lifted its position in shares of Haleon by 3.2% during the third quarter. Peapack Gladstone Financial Corp now owns 44,844 shares of the company's stock worth $474,000 after purchasing an additional 1,390 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Performance

Shares of Haleon stock traded up $0.06 during trading hours on Friday, reaching $10.45. The company's stock had a trading volume of 10,381,006 shares, compared to its average volume of 6,535,003. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The company's 50 day simple moving average is $9.66 and its 200 day simple moving average is $9.86. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a market cap of $47.29 billion, a P/E ratio of 30.72, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25.

Remove Ads

Haleon (NYSE:HLN - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The firm had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. As a group, analysts expect that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The business also recently disclosed a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a dividend of $0.1166 per share. The ex-dividend date is Friday, April 25th. This represents a yield of 1.6%. This is a positive change from Haleon's previous -- dividend of $0.05. Haleon's payout ratio is currently 58.97%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. HSBC reaffirmed a "hold" rating on shares of Haleon in a research note on Wednesday. Hsbc Global Res cut Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. Sanford C. Bernstein lowered Haleon from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 8th. Finally, Morgan Stanley cut Haleon from an "overweight" rating to an "equal weight" rating in a research note on Friday, January 10th. Five analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.